Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Wuhan Healthgen Biotechnology's EV-to-FCF or its related term are showing as below:
SHSE:688765'
s EV-to-FCF Range Over the Past 10 Years
Min: -73.9 Med: -34.31 Max: -18.43
Current: -22.47
During the past 12 years, the highest EV-to-FCF of Wuhan Healthgen Biotechnology was -18.43. The lowest was -73.90. And the median was -34.31.
SHSE:688765's EV-to-FCF is ranked worse than 100% of 564
companies
in the Drug Manufacturers industry
Industry Median: 20.895
vs SHSE:688765: -22.47
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Wuhan Healthgen Biotechnology's PE Ratio (TTM) for today is calculated as:
Wuhan Healthgen Biotechnology's share price for today is ¥54.61.
Wuhan Healthgen Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-0.476.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Wuhan Healthgen Biotechnology EV-to-FCF Related Terms
Wuhan Healthgen Biotechnology EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Wuhan Healthgen Biotechnology's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wuhan Healthgen Biotechnology EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wuhan Healthgen Biotechnology's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Wuhan Healthgen Biotechnology's EV-to-FCF falls into.
Wuhan Healthgen Biotechnology's current Enterprise Value is ¥18,769.81 Mil.
Wuhan Healthgen Biotechnology's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-835.36 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wuhan Healthgen Biotechnology (SHSE:688765) has a EV-to-FCF of -22.47 as of Jul. 16, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Wuhan Healthgen Biotechnology and its competitors. According to the industry distribution chart, Wuhan Healthgen Biotechnology ranks #999999 out of 564 companies in the Drug Manufacturers industry.
Is Wuhan Healthgen Biotechnology's EV-to-FCF too high?
Wuhan Healthgen Biotechnology's current EV-to-FCF is -22.47. Based on the distribution chart, Wuhan Healthgen Biotechnology ranks #999999 out of 564 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Wuhan Healthgen Biotechnology has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Wuhan Healthgen Biotechnology's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Wuhan Healthgen Biotechnology ranks #999999 out of 564 companies for EV-to-FCF. This places Wuhan Healthgen Biotechnology in the lower half of its industry. The industry median EV-to-FCF is 20.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.90, based on 564 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Wuhan Healthgen Biotechnology and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wuhan Healthgen Biotechnology's current EV-to-FCF is -22.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuhan Healthgen Biotechnology stock overvalued right now?
Wuhan Healthgen Biotechnology (SHSE:688765) has a current EV-to-FCF of -22.47. The current EV-to-FCF is -22.47. Wuhan Healthgen Biotechnology's overall GF Score™ is 19/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Wuhan Healthgen Biotechnology (SHSE:688765), the current EV-to-FCF is -22.47 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Wuhan Healthgen Biotechnology Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688765 has been successfully added to your 
